# EDGAR Filing Document

**Accession Number:** 0001932393
**File Stem:** 0001932393-26-000013
**Filing Date:** 2026-3
**Character Count:** 10533
**Document Hash:** 63ed229054f6aa31e8fbda432583d96a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001932393-26-000013.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0001932393-26-000013

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260313

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GE HealthCare Technologies Inc.
- **CENTRAL INDEX KEY:** 0001932393
- **STANDARD INDUSTRIAL CLASSIFICATION:** X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 882515116
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41528
- **FILM NUMBER:** 26759329

**BUSINESS ADDRESS:**
- **STREET 1:** 500 WEST MONROE STREET
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
- **BUSINESS PHONE:** 833-735-1139

**MAIL ADDRESS:**
- **STREET 1:** 500 WEST MONROE STREET
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GE Healthcare Holding LLC
- **DATE OF NAME CHANGE:** 20220603

?xml version='1.0' encoding='ASCII'? gehc-20260313

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **March 13, 2026** 

**<u>GE HEALTHCARE TECHNOLOGIES INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **001-41528** | **88-2515116** |
| (State or other jurisdiction <br>of incorporation) | (State or other jurisdiction <br>of incorporation) | (State or other jurisdiction <br>of incorporation) | (Commission<br> File Number) | (IRS Employer<br>Identification No.) |
| **500 W. Monroe Street,** | **Chicago,** | **IL** |  | **60661** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) |  | (Zip Code) |

---

(Registrant's telephone number, including area code) **<u>(833) 735-1139</u>**

______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.01 per share | GEHC | The Nasdaq Stock Market LLC |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). | |
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 13, 2026, the Board of Directors (the "Board") of GE HealthCare Technologies Inc. (the "Company") appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo's term will expire at the Company's 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and Compensation Committee of the Board, effective immediately.

Mr. Lobo will receive compensation in accordance with the Company's compensation program for non-employee directors, which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on April 10, 2025. The Company will also enter into an indemnification agreement with Mr. Lobo. The form of indemnification agreement is included as Exhibit 10.3 to the Company's Annual Report on Form 10-K filed with the SEC on February 4, 2026.

There is no arrangement or understanding between Mr. Lobo and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Lobo and the Company that would be reportable under Item 404(a) of Regulation S-K.

Also on March 13, 2026, each of Risa Lavizzo-Mourey and Tomislav Mihaljevic informed the Board that they would not stand for re-election to the Board at the Company's 2026 Annual Meeting of Stockholders due to other commitments. Neither Dr. Lavizzo-Mourey's nor Dr. Mihaljevic's decision was a result of any disagreement on a matter related to the Company's operations, policies, or practices.

**Item 7.01 Regulation FD Disclosure.**

On March 17, 2026, the Company issued a press release announcing the appointment of Kevin A. Lobo to its Board. A copy of the press release is furnished as Exhibit 99.

The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| **99** | [Press Release of GE HealthCare Technologies Inc., dated March 17, 2026.](lobopr-final.htm) |
| **104** | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | GE HealthCare Technologies Inc. |
| | (Registrant) |
| Date: March 17, 2026 | /s/ Frank R. Jimenez |
| | Frank R. Jimenez, General Counsel and Corporate Secretary<br>(authorized signatory) |

---

## Ex-99

![image_0.jpg](image_0.jpg)

GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

**CHICAGO —(BUSINESS WIRE)— March 17, 2026**— GE HealthCare (Nasdaq: GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE: SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities.

"Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and sustainable future for healthcare," said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. "We look forward to benefiting from his perspective as we execute on our growth and innovation priorities."

Mr. Lobo has served as the Chief Executive Officer of Stryker Corporation since October 2012 and as chair of the Stryker Board of Directors since July 2014. Prior to this, he held leadership positions in Stryker's Orthopedics Group and Neurotechnology and Spine Group. Mr. Lobo's depth of experience includes operations leadership at Johnson & Johnson, including as President of Ethicon Endo Strategy, and Rhône-Poulenc, a chemical and pharmaceutical company. Earlier in his career, he held finance roles of increasing responsibility at KPMG, Unilever and Kraft Canada.

"GE HealthCare plays a critical role in shaping the future of healthcare through advanced technology, novel pharmaceutical diagnostics, and global reach," said Kevin Lobo. "I look forward to serving on its Board and working with the management team as it executes on its strategy to enable more precise patient care, drive growth, and create long-term value."

 **Media Contact:**

Jennifer Fox

Head of External Corporate Communications

+1 414 530 3027

<u>jennifer.r.fox@gehealthcare.com</u> 

**Investor Relations Contact:** 

Carolynne Borders

+1-631-662-4317

<u>carolynne.borders@gehealthcare.com</u>

**About GE HealthCare Technologies Inc.** 

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care

------

Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among <u>2026</u> *<u>Fortune World's Most Admired Companies™</u>.* 

Follow us on <u>LinkedIn</u>, <u>Facebook</u>, <u>Instagram</u>, or visit our website for our <u>latest news</u> and <u>perspectives</u>.

<br>